Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2023-10-03 Regulatory Filings
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-10-03 English
PRIMARY DOCUMENT
Director's Dealing
2023-08-22 English
Regulatory Filings 2023
Regulatory Filings
2023-08-18 English
Regulatory Filings 2023
Regulatory Filings
2023-08-18 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to a 424(b)(5) registration statement, describing an offering of common stock up to $150 million under a Controlled Equity Offering Sales Agreement. It includes detailed information about the offering, risk factors, use of proceeds, dilution, plan of distribution, and legal matters. The document is not a financial report, earnings release, or management discussion, but rather a capital raising document describing the terms and conditions of a stock offering. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it is not merely an announcement or a brief notice, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2023-08-17 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references the Securities Act of 1933 and the filing number 333-273910. The content is a formal correspondence related to a registration statement becoming effective, not the registration statement itself or any financial report. The document length is short (1718 characters) and it is a communication about a regulatory filing process. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-08-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.